| Literature DB >> 29887848 |
Feng-Jui Chen1, Tsai-Ling Lauderdale1, Chen-Hsiang Lee2, Yu-Chieh Hsu1, I-Wen Huang1, Pei-Chi Hsu1, Chung-Shi Yang3.
Abstract
We previously reported the sequential recovery of daptomycin-nonsusceptible MRSA clinical isolates with an L431F substitution in the MprF protein. The aim of the present study is to determine the effect of this mutation by replacing the mprF gene on the chromosome of a daptomycin-susceptible progenitor strain, CGK5, to obtain CGK5mut having the L431F MprF mutation. Compared to CGK5, the daptomycin and vancomycin MICs of CGK5mut increased from 0.5 to 3 μg/ml and from 1.5 to 3 μg/ml, respectively; however, its oxacillin MIC decreased from 128 to 1 μg/ml in medium without added 2% NaCl. The expression levels of vraSR and several other cell-wall synthesis-related genes were significantly increased in CGK5mut, and the mutant also had significantly reduced negative cell membrane charge, thicker cell wall, and longer doubling time. These features were abolished in the reverse mutant carrying F431L MprF, confirming the pleiotropic effects of the L431F MprF mutation. We believe that this is the first work that shows a single MprF missense mutation can lead to not only changes in the cell membrane but also increased expression of vraSR and subsequently increased resistance to daptomycin and vancomycin while simultaneously conferring increased susceptibility to oxacillin in an isogenic MRSA strain.Entities:
Keywords: MRSA; daptomycin; drug resistance; evolution; oxacillin; vancomycin
Year: 2018 PMID: 29887848 PMCID: PMC5980971 DOI: 10.3389/fmicb.2018.01086
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Bacterial strains and plasmids used in this study.
| Strain/plasmid | Description | Source or Reference |
|---|---|---|
| | ||
| XL10-Gold | Ultra-competent cell for site-directed mutagenesis | Stratagene |
| Genehogs | Electrocompetent cells | Invitrogen |
| | ||
| RN4220 | Restriction-deficient derivative of 8325-4 | |
| RN6911 | RN6390B | |
| Z172 | Clinical VISA isolate with | |
| CGK5 | Daptomycin-susceptible MRSA | |
| CGK5mut | MprF L431F derivative of CGK5 | This study |
| CGK5mutR | Reversed derivative of CGK5mut with MprF containing F431L and a new EcoRV site | This study |
| CGK6 | Daptomycin-non-susceptible MRSA | |
| | ||
| 2V076 | Clinical isolate with | This study |
| pMAD | pE194ts derivative for gene replacement in Gram-positive bacteria | |
| pMAD-SAT4-tetM | Modified pMAD with | This study |
| pMprFmut | The | This study |
| pMprF5 | The | This study |
| pMprFmutR | A silent EcoRV site was introduced into the middle of the | This study |
| pluxT2 | pSK5630 derivative containing | |
| pluxT2-SPC | pluxT2 with | This study |
Primers used in this study.
| Primers | Nucleotide sequence (5′–3′)a |
|---|---|
| CG | |
| ACGC | |
| P-AGAGAGGCGGGAACAGTG | |
| ACGC | |
| P-GGAGATTCCTTTACAAATATG | |
| ACGC | |
| CG | |
| TCC | |
| P- | |
| TCATTATTGCTGCATTATCTGGA | |
| TTTTCCTCAGGGACACCTAAAG | |
| GCCAGATTCAGGTACACG | |
| TCTGAGTCGTCGCTTC | |
| AAAACATCTAAGCCTATCCCATTG | |
| TTTGAATCGCTTTAACTGCTTGAT | |
| AAAATAAGAGGTGGACGCACA | |
| ACTGTTTTTCGCGCCACT | |
| TCGGTGCAATTGGTAAGAACT | |
| TTAATGTTGAGGCACCTTCAGA | |
| TAGCGACAGAGATGTGC | |
| TTGTGACATAGCCTGTTG | |
| AATAAATCAAGCGAGCTATATTGTTG | |
| ACGATGCGAAGCTTTGACTAC | |
| CGTTAATTGAAGCAGGCTATGTG | |
| TGGTGTTGGATTCAATTCAGATT | |
| P-AAAGTTCTCGTTCGGAGG | |
| TCC | |
| P | CG |
| P | ACGC |
| P | CG |
| P | ACGC |